The mosaic bioprosthesis in the aortic position: Seven years' results

Journal of Heart Valve Disease

Volumn 12, Issue 3, 2003, Pages 354-361

  Gansera, Brigitte ^a   Botzenhardt, Florian ^a   Günzinger, Ralf ^a   Spiliopoulos, Kyriakos ^a   Angelis, Ilias ^a   Kemkes, Bernhard M ^a  

^a KLINIKUM BOGENHAUSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; PHENPROCOUMON; WARFARIN;

AORTA VALVE DISEASE; AORTA VALVE PROSTHESIS; AORTA VALVE REGURGITATION; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTICLE; BLEEDING; CONTROLLED STUDY; DETERIORATION; ENDOCARDITIS; EXPLANT; FOLLOW UP; GERMANY; HEART HEMODYNAMICS; HEART LEFT VENTRICLE MASS; HEART VALVE BIOPROSTHESIS; HUMAN; INTRACARDIAC THROMBOSIS; MAJOR CLINICAL STUDY; MORTALITY; OUTCOMES RESEARCH; PERIODIC MEDICAL EXAMINATION; POSTOPERATIVE PERIOD; PRESSURE GRADIENT; PRIORITY JOURNAL; REOPERATION; SURGICAL TECHNIQUE; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; AORTIC VALVE INSUFFICIENCY; AORTIC VALVE STENOSIS; BIOPROSTHESIS; COHORT STUDIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSTHESIS DESIGN; PROSTHESIS FAILURE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0038312997     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Carpentier A, Lemaigre G, Robert L, Carpentier S, Dubost C. Biological factors affecting long-term results of valvular heterografts. J Thorac Cardiovasc Surg 1969;58:467
2. Vesley I. Analysis of the Medtronic Intact bioprosthesis valve. Effects of 'zero-pressure' fixation. J Thorac Cardiovasc Surg 1991;101:90-99
3. Vesley I, Lozon A, Talman E. Is zero-pressure fixation of bioprosthetic valves truly stress free? J Thorac Cardiovasc Surg 1993;106:288-298
4. Girardot MN, Girardot JM, Torrianni M. Alpha-aminooleic acid (AOA) anticalcification effect on glutaraldehyde fixed heart valves: Shelf-life studies. In: Gabbay S, Frater RWM (ed.) First edition. Silent Partners, Austin, TX, 1994:41-52
5. Levy RJ. Glutaraldehyde and the calcification mechanism of bioprosthetic heart valves. J Heart Valve Dis 1994;3:101-104
6. Schoen FJ, Tsao JW, Levy RJ. Calcification of bovine pericardium used in cardiac valve bioprosthesis: Implications for the mechanisms of bioprosthetic tissue mineralization. Am J Pathol 1986;123:134-145
7. Walther T, Falk V, Diegeler A, et al. Effectiveness of different anticalcification treatments for stentless aortic bioprostheses. Thorac Cardiovasc Surg 1999;47:23-25
8. Chen W, Schoen FJ, Levy RJ. Mechanism of efficacy of 2-amino oleic acid for inhibition of calcification of glutaraldehyde-pretreated porcine bioprosthetic heart valves. Circulation 1994;90:323-329
9. Duarte IG, MacDonald MJ, Cooper WA, et al. In vivo hemodynamic, histologic and antimineralization characteristics of the Mosaic bioprosthesis. Ann Thorac Surg 2001;71:92-99
10. Eichinger WB, Guenzinger R, Botzenhardt F, Simmerl D, Gansera B, Kemkes BM. The Mosaic bioprosthesis in the aortic position at five years. J Heart Valve Dis 2000;9:653-660
11. Craver J. CarboMedics prosthetic heart valve. Eur J Cardiothorac Surg 1999;15(suppl.I):3-11
12. Edmunds LH, Clark RE, Cohn LH, Grunkemeier GL, Miller CM, Weisel RD. Guidelines for reporting morbidity and mortality after cardiac valvular operations. Ann Thorac Surg 1996;62:932-935
13. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457
14. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613-618
15. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986;57:450-458
16. Aupart MR, Neville P, Dreyfus X, Meurisse Y, Sirinelli A, Marchand M. The Carpentier-Edwards pericardial aortic valve: Intermediate results in 420 patients. Eur J Cardiothorac Surg 1994;8:277-280
17. Eichinger WB, Schütz A, Simmerl D, et al. The Mosaic bioprosthesis in the aortic position: Hemodynamic performance after 2 years. Ann Thorac Surg 1998;66:126-129
18. Wong SP, Legget ME, Greaves SC, Barratt-Boyes BG, Milsom FP, Raudkivi PJ. Early experience with the Mosaic bioprosthesis: A new generation porcine valve. Ann Thorac Surg 2000;69:1846-1850
19. Thomson DJ, Jamieson WR, Dumesnil JG, et al. Medtronic Mosaic porcine bioprosthesis: Midterm investigational trial results. Ann Thorac Surg 2001;71:S269-S272
20. Dumesnil J, LeBlanc MH, Cartier P, et al. Hemodynamic features of the Freestyle aortic bioprosthesis compared with stented bioprosthesis. Ann Thorac Surg 1998;66:S130-S133
21. Eriksson MJ, Brodin LA, Dellgren GN, Radegran K. Rest and exercise hemodynamics of an extended stentless aortic bioprosthesis. J Heart Valve Dis 1997;6:653-660
22. Del Rizzo DF, Abdoh A. Clinical and hemodynamic comparison of the Medtronic Freestyle and Toronto SPV stentless valves. J Card Surg 1998;13:398-407
23. Hvass U, O'Brien M. The stentless Cryolife-O'Brien aortic porcine xenograft: A 5-year follow-up. Ann Thorac Surg 1998;66:134-138
24. Lemieux MD, Jamieson WRE, Landymore RW, et al. Medtronic Intact porcine bioprosthesis: Clinical performance to seven years. Ann Thorac Surg 1995;60:258-263
25. Jamieson WRE, Tyers GF, Miyagishima RT, Germann E, Janusz MT, Ling H. Carpentier-Edwards porcine bioprosthesis. Comparison of standard and supra-annular prosthesis at 7 years. Circulation 1991;(Suppl.3):145-152
26. Grunkemeier GL, Bodnar E. Comparative assessment of bioprosthesis durability in the aortic position. J Heart Valve Dis 1995;4:49-55